Replies to post #11692 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

GDUFA seems to be a complete failure in terms of expediting the review process from a generic-company standpoint.

We can’t really say the GDUFA regs are not working unless 5/24/14 passes without a decision on the Copaxone ANDA.